The drug manufacturer, based in Minnesota, US, announced the commercialisation of the drug, as the third generic product introduced by ANI since the beginning of 2019.
Ranitidine hydrochloride, an oral histamine H2-receptor antagonist, will be distributed in dosage forms of 150mg and 300mg. According to the company, the current annual US market for this product is approximately $40m (€35.2m).
The ranitidine capsules are indicated in the treatment of active duodenal ulcers, hypersecretory conditions, gastric ulcers, gastroesophageal reflux disease and erosive esophagitis.
This launch, which brings the company’s generic portfolio to 34 commercial products, was the first one to occur through ANI’s partnership with New Jersey, US-based manufacturer, Appco Pharma, which began in March 2018.
Following the announcement of the launch, ANI's CEO, Arthur Przybyl said, “We look forward to additional future launches through this partnership as we advance our collaboration.”
ANI’s targeted areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations, involving extended release and combination products.
In March 2019, the company launched methylphenidate hydrochloride extended release tablets, indicated as a treatment for attention deficit hyperactivity disorder and erythromycin ethylsuccinate for oral suspension, as a treatment for various infections.